PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.501
https://www.valueinhealthjournal.com/article/S1098-3015(11)02063-8/fulltext
Title :
PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02063-8&doi=10.1016/j.jval.2011.08.501
First page :
A323
Section Title :
Neurological Disorders
Open access? :
No
Section Order :
472